BackPT Diagnos Laboratorium Utama Tbk Overview

PT Diagnos Laboratorium Utama Tbk Receivables

Latest receivables for DGNS.JK: $45B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$45.07B
↓ 18.57% YoYΔ $-10.28B vs prior year quarter

Peer trimmed avg / median

Loading

PT Diagnos Laboratorium Utama Tbk Receivables History

Loading

PT Diagnos Laboratorium Utama Tbk vs. peers: Receivables Comparison

Loading

PT Diagnos Laboratorium Utama Tbk Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

PT Diagnos Laboratorium Utama Tbk (DGNS.JK) FAQ

As of the most recent data (September 2026), DGNS.JK shows a receivables of $45B. That compares with $55B in the prior-year period — down 18.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DGNS.JK's receivables is now $45B (was $55B) — a 18.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PT Diagnos Laboratorium Utama Tbk is outperforming or lagging.

Tracking DGNS.JK's receivables over time shows whether PT Diagnos Laboratorium Utama Tbk is scaling, shrinking, or reshaping that part of the business. The current reading is $45B That compares with $55B in the prior-year period — down 18.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has PT Diagnos Laboratorium Utama Tbk's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $45B) with ownership activity and broader fundamentals.